Overview

Stand UP to Rheumatoid Arthritis (SUPRA)

Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
Phase:
N/A
Details
Lead Sponsor:
Marie Hudson, MD
Collaborators:
Lady Davis Institute
McGill University Health Centre/Research Institute of the McGill University Health Centre
Montreal General Hospital
Treatments:
Adalimumab
Etanercept
Golimumab
Tofacitinib
Upadacitinib